Cargando…

Intravenous tissue plasminogen activator for ischemic stroke in early pregnancy dosed by actual body weight

INTRODUCTION: Few published reports highlight intravenous tissue plasminogen activator use during the first trimester of pregnancy and provide outcomes for mother and fetus. Little guidance is available regarding body weight dosing of intravenous tissue plasminogen activator during pregnancy. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peksa, Gary D, Ostrem, Jamie, Davis, Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378419/ https://www.ncbi.nlm.nih.gov/pubmed/30800307 http://dx.doi.org/10.1177/2050313X19828247

Ejemplares similares

Intravenous tissue plasminogen activator, ischemic stroke, and the risk of Kounis Syndrome
por: Kounis, Nicholas G., et al.
Publicado: (2011)

Intravenous Tissue Plasminogen Activator for an Ischemic Stroke with Occult Double Primary Cancer
por: Yoneda, Yukihiro, et al.
Publicado: (2014)

Different Doses of Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: A Network Meta-Analysis
por: Li, Bing-Hu, et al.
Publicado: (2022)

Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke
por: Lin, Cheryl B, et al.
Publicado: (2015)

Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2016)

Acute myocardial infarction following intravenous tissue plasminogen activator for acute ischemic stroke: An unknown danger
por: Sweta, Adatia, et al.
Publicado: (2010)

Intravenous Tissue Plasminogen Activator Improves the Outcome in Very Elderly Korean Patients with Acute Ischemic Stroke
por: Choi, Jay Chol, et al.
Publicado: (2015)

Imaging Evidence for Cerebral Hyperperfusion Syndrome after Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke
por: Zhang, Yi, et al.
Publicado: (2016)

Genome response to tissue plasminogen activator in experimental ischemic stroke
por: Jickling, Glen C, et al.
Publicado: (2010)

Comparison of Effectiveness and Safety of Low-Dose Versus Standard-Dose Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke: A Meta-Analysis
por: Karedath, Jithin, et al.
Publicado: (2023)

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry
por: Matsuo, Ryu, et al.
Publicado: (2014)

Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis in a Patient with Acute Ischemic Stroke Secondary to Aortic Dissection
por: Hong, Keun-Sik, et al.
Publicado: (2009)

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
por: Chapman, Sherita N, et al.
Publicado: (2014)

Does Intravenous Administration of Recombinant Tissue Plasminogen Activator for Ischemic Stroke can Cause Inferior Myocardial Infarction?
por: Almasi, Mostafa, et al.
Publicado: (2016)

Carotid Artery Stenting for Acute Ischemic Stroke Patients after Intravenous Recombinant Tissue Plasminogen Activator Treatment
por: Deguchi, Ichiro, et al.
Publicado: (2016)

Age-specific Cost Effectiveness of Using Intravenous Recombinant Tissue Plasminogen Activator for Treating Acute Ischemic Stroke
por: Joo, Heesoo, et al.
Publicado: (2017)

Low-dose intravenous tissue plasminogen activator for acute ischaemic stroke: an alternative or a new standard?
por: Dong, Yi, et al.
Publicado: (2016)

Emergent Double-barrel Bypass Shortly after Intravenous Administration of Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
por: Choi, Joon-Ho, et al.
Publicado: (2016)

The Utility of Automated ASPECTS in Acute Ischemic Stroke for Intravenous Recombinant Tissue Plasminogen Activator (IV-rtPA) Therapy
por: Shibata, Soichiro, et al.
Publicado: (2022)

Risk of pneumonia associated with zero‐degree head positioning in acute ischemic stroke patients treated with intravenous tissue plasminogen activator
por: Palazzo, Paola, et al.
Publicado: (2016)

Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2018)

Protection against brain injury after ischemic stroke by intravenous human amnion epithelial cells in combination with tissue plasminogen activator
por: Barreto-Arce, Liz J., et al.
Publicado: (2023)

Unruptured Cerebral Aneurysm Detected after Intravenous Tissue Plasminogen Activator for Stroke
por: Yoneda, Yukihiro, et al.
Publicado: (2009)

Medicolegal Considerations with Intravenous Tissue Plasminogen Activator in Stroke: A Systematic Review
por: Bhatt, Archit, et al.
Publicado: (2013)

Low-Dose Versus Standard-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke in Asian Populations: A Meta-Analysis
por: Liu, Meng-Dong, et al.
Publicado: (2015)

Tissue plasminogen activator and patients with acute ischemic stroke: The litigation landscape
por: Ganti, Latha, et al.
Publicado: (2022)

Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight
por: Fox, Ashley N., et al.
Publicado: (2019)

DRAGON score predicts functional outcomes in acute ischemic stroke patients receiving both intravenous tissue plasminogen activator and endovascular therapy
por: Wang, Arthur, et al.
Publicado: (2017)

Outcomes of Endovascular Mechanical Thrombectomy and Intravenous Tissue Plasminogen Activator for the Treatment of Vertebrobasilar Stroke
por: Brinjikji, Waleed, et al.
Publicado: (2014)

Medico-Legal Aspects of Using Tissue Plasminogen Activator in Acute Ischemic Stroke
por: Bruce, Nhu T., et al.
Publicado: (2011)

Association of Geographical Factors With Administration of Tissue Plasminogen Activator for Acute Ischemic Stroke
por: Kunisawa, Susumu, et al.
Publicado: (2013)

Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator
por: Liu, Shi-Ying, et al.
Publicado: (2018)

Coronary aspiration thrombectomy after using intravenous recombinant tissue plasminogen activator in a patient with acute ischemic stroke: a case report
por: Mai Duy, Ton, et al.
Publicado: (2019)

Mechanical Thrombectomy With and Without Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis Using Nested Knowledge
por: Adusumilli, Gautam, et al.
Publicado: (2021)

Tissue plasminogen activator; identifying major barriers related to intravenous injection in ischemic acute cerebral infraction
por: Khorvash, Fariborz, et al.
Publicado: (2017)

Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers
por: Aparicio, Hugo J., et al.
Publicado: (2015)

Predictors of Intracerebral Hemorrhage in Acute Stroke Patients Receiving Intravenous Recombinant Tissue Plasminogen Activator
por: Chenna, Vijay, et al.
Publicado: (2018)

Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator: Erratum
Publicado: (2019)

Angioedema Secondary to IV Tissue Plasminogen Activator Administration for Treatment of Acute Ischemic Stroke
por: Chaucer, Benjamin, et al.
Publicado: (2018)

The influence of dehydration on the prognosis of acute ischemic stroke for patients treated with tissue plasminogen activator
por: Wu, Fei-Fan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rno2j39jairamunbptl7f20i8r